home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Gleevec May Cause Heart Problems

  August, 2 2006 9:09
your information resource in human molecular genetics
Imatinib mesylate (Gleevec), a drug used to treat chronic myelogenous leukemia (CML), can kill heart cells, according to a paper in the August 2006 issue of Nature Medicine.

Imatinib acts by inhibiting the activity of the protein Bcr-Abl, the causal agent in CML. Thomas Force and his colleagues report on ten people who developed severe congestive heart failure while on imatinib and show that mice treated with the drug develop heart pathology. Microscopic and biochemical analyses of human and mice hearts treated with imatinib suggest that the drug is toxic to cardiac cells. This effect seemed to depend on the action of imatinib over Bcr-Abl and not on other targets.

So, a toxic effect on the heart is an unanticipated side effect of imatinib. The authors suggest that patients who are on imatinib should be followed closely for symptoms of cardiac dysfunction.

Author Contact:

Thomas Force (Jefferson Medical College, Philadelphia, PA, USA)
E-mail: thomas.force@jefferson.edu

Abstract available online.

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2021 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.